Cargando…

Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines

BACKGROUND: Despite the large-scale clinical application of programmed death-ligand 1 (PD-L1) monoclonal antibody, reduction in its clinical response rate has become a gradual problem. As such, use of PD-L1 monoclonal antibody in combination with other anticarcinoma drugs has been the main strategy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Qian, Wu, Changping, Chen, Jianping, Wang, Weibing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381951/ https://www.ncbi.nlm.nih.gov/pubmed/32724815 http://dx.doi.org/10.1155/2020/8910183

Ejemplares similares

Decreased IL-37 expression in hepatocellular carcinoma tissues and liver cancer cell lines
por: Li, Peng, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

IL-10 promoter hypomethylation is associated with increased IL-10 expression and poor survival in hepatocellular carcinoma
por: Zhang, Xianjing, et al.
Publicado: (2019)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Jimbu, Laura, et al.
Publicado: (2021)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
por: Numata, Yasunao, et al.
Publicado: (2022)

Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
por: Davidsson, Sabina, et al.
Publicado: (2022)

Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma
por: Lou, Jian, et al.
Publicado: (2017)

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
por: Jung, Hae Il, et al.
Publicado: (2017)

PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
por: Guo, Shuang, et al.
Publicado: (2022)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma
por: Xie, Tianshu, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma
por: Liu, Yan, et al.
Publicado: (2017)

M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
por: Zong, Zhaoyun, et al.
Publicado: (2019)

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
por: Xu, Da-Lai, et al.
Publicado: (2022)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

IL-32 and IL-34 in hepatocellular carcinoma
por: Si, Yang, et al.
Publicado: (2022)

Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2023)

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis
por: Zhang, Qian, et al.
Publicado: (2020)

Terahertz in-line digital holography of human hepatocellular carcinoma tissue
por: Rong, Lu, et al.
Publicado: (2015)

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
por: Yasuoka, Hidetaka, et al.
Publicado: (2020)

Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab
por: Yuan, Yazhen, et al.
Publicado: (2022)

The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma
por: Hlaing, Sa Tin Myo, et al.
Publicado: (2023)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2020)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Control of Adaptive Immune Responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2
por: Wang, Jinhai, et al.
Publicado: (2012)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2023)

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis
por: Yang, Yao, et al.
Publicado: (2023)

Retracted: Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

IL-10/IL-10 receptor 1 pathway promotes the viability and collagen synthesis of pulmonary fibroblasts originated from interstitial pneumonia tissues
por: Ye, Hong, et al.
Publicado: (2022)

Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
por: Martomo, Stella A., et al.
Publicado: (2022)

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2020)

PD-1 and ICOS counter-regulate tissue resident regulatory T cell development and IL-10 production during flu
por: McGee, Michael C., et al.
Publicado: (2022)

Vitamin K Contents in Liver Tissue of Hepatocellular Carcinoma Patients
por: Miyakawa, Takayuki, et al.
Publicado: (2000)

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
por: He, Gaixia, et al.
Publicado: (2015)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Ye, Xiangdong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mm4l2udpf0e0uqovoslepjfc17